Immune Response to Bivalent and Tetravalent Human Papillomavirus Vaccine in HIV Infected Adults

Trial Profile

Immune Response to Bivalent and Tetravalent Human Papillomavirus Vaccine in HIV Infected Adults

Completed
Phase of Trial: Phase IV

Latest Information Update: 16 Feb 2016

At a glance

  • Drugs Human papillomavirus vaccine recombinant bivalent Japan Vaccine/MedImmune (Primary) ; Human papillomavirus vaccine recombinant quadrivalent Merck
  • Indications Human papillomavirus infections
  • Focus Pharmacodynamics
  • Acronyms HIPAVAC
  • Most Recent Events

    • 07 Jun 2017 Biomarkers information updated
    • 16 Feb 2016 Results published in the Vaccine
    • 23 Nov 2013 Results published in the Journal of Infectious Diseases.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top